PRDM16 (1p36) translocations define a distinct entity of myeloid malignancies with poor prognosis but may also occur in lymphoid malignancies
Francois P. Duhoux
Centre for Human Genetics, Cliniques universitaires Saint-Luc, Université catholique de Louvain
Search for more papers by this authorGeneviève Ameye
Centre for Human Genetics, Cliniques universitaires Saint-Luc, Université catholique de Louvain
Search for more papers by this authorCarmen P. Montano-Almendras
de Duve Institute, Université catholique de Louvain, Brussels, Belgium
Search for more papers by this authorKhadija Bahloula
Centre for Human Genetics, Cliniques universitaires Saint-Luc, Université catholique de Louvain
Search for more papers by this authorMarie J. Mozziconacci
Institut Paoli-Calmettes, Marseilles, France
Search for more papers by this authorIwona Wlodarska
Centre for Human Genetics, K.U. Leuven, Leuven, Belgium
Search for more papers by this authorLucienne Michaux
Centre for Human Genetics, K.U. Leuven, Leuven, Belgium
Search for more papers by this authorFrank Speleman
Centre for Medical Genetics, Ghent University Hospital, Ghent, Belgium
Search for more papers by this authorChristian Herens
Centre de Génétique humaine, CHU, Liège, Belgium
Search for more papers by this authorKatrina Rack
Institut de Pathologie et de Génétique, Gosselies, Belgium
Search for more papers by this authorSylvie Taviaux
Hôpital Arnaud de Villeneuve, Montpellier, France
Search for more papers by this authorDominique Latinne
Immuno-Haematology Department, Cliniques universitaires Saint- Luc, Université catholique de Louvain, Brussels, Belgium
Search for more papers by this authorJeanne M. Libouton
Centre for Human Genetics, Cliniques universitaires Saint-Luc, Université catholique de Louvain
Search for more papers by this authorJean-Baptiste Demoulin
de Duve Institute, Université catholique de Louvain, Brussels, Belgium
Search for more papers by this authorHélène A. Poirel
Centre for Human Genetics, Cliniques universitaires Saint-Luc, Université catholique de Louvain
Search for more papers by this authoron behalf of the Groupe Francophone de Cytogénétique Hématologique (GFCH) and of the Belgian Cytogenetic Group for Haematology and Oncology (BCG-HO)
Search for more papers by this authorFrancois P. Duhoux
Centre for Human Genetics, Cliniques universitaires Saint-Luc, Université catholique de Louvain
Search for more papers by this authorGeneviève Ameye
Centre for Human Genetics, Cliniques universitaires Saint-Luc, Université catholique de Louvain
Search for more papers by this authorCarmen P. Montano-Almendras
de Duve Institute, Université catholique de Louvain, Brussels, Belgium
Search for more papers by this authorKhadija Bahloula
Centre for Human Genetics, Cliniques universitaires Saint-Luc, Université catholique de Louvain
Search for more papers by this authorMarie J. Mozziconacci
Institut Paoli-Calmettes, Marseilles, France
Search for more papers by this authorIwona Wlodarska
Centre for Human Genetics, K.U. Leuven, Leuven, Belgium
Search for more papers by this authorLucienne Michaux
Centre for Human Genetics, K.U. Leuven, Leuven, Belgium
Search for more papers by this authorFrank Speleman
Centre for Medical Genetics, Ghent University Hospital, Ghent, Belgium
Search for more papers by this authorChristian Herens
Centre de Génétique humaine, CHU, Liège, Belgium
Search for more papers by this authorKatrina Rack
Institut de Pathologie et de Génétique, Gosselies, Belgium
Search for more papers by this authorSylvie Taviaux
Hôpital Arnaud de Villeneuve, Montpellier, France
Search for more papers by this authorDominique Latinne
Immuno-Haematology Department, Cliniques universitaires Saint- Luc, Université catholique de Louvain, Brussels, Belgium
Search for more papers by this authorJeanne M. Libouton
Centre for Human Genetics, Cliniques universitaires Saint-Luc, Université catholique de Louvain
Search for more papers by this authorJean-Baptiste Demoulin
de Duve Institute, Université catholique de Louvain, Brussels, Belgium
Search for more papers by this authorHélène A. Poirel
Centre for Human Genetics, Cliniques universitaires Saint-Luc, Université catholique de Louvain
Search for more papers by this authoron behalf of the Groupe Francophone de Cytogénétique Hématologique (GFCH) and of the Belgian Cytogenetic Group for Haematology and Oncology (BCG-HO)
Search for more papers by this authorSummary
The PRDM16 (1p36) gene is rearranged in acute myeloid leukaemia (AML) and myelodysplastic syndrome (MDS) with t(1;3)(p36;q21), sharing characteristics with AML and MDS with MECOM (3q26.2) translocations. We used fluorescence in situ hybridization to study 39 haematological malignancies with translocations involving PRDM16 to assess the precise breakpoint on 1p36 and the identity of the partner locus. Reverse-transcription polymerase chain reaction (PCR) was performed in selected cases in order to confirm the partner locus. PRDM16 expression studies were performed on bone marrow samples of patients, normal controls and CD34+ cells using TaqMan real-time quantitative PCR. PRDM16 was rearranged with the RPN1 (3q21) locus in 30 cases and with other loci in nine cases. The diagnosis was AML or MDS in most cases, except for two cases of lymphoid proliferation. We identified novel translocation partners of PRDM16, including the transcription factors ETV6 and IKZF1. Translocations involving PRDM16 lead to its overexpression irrespective of the consequence of the rearrangement (fusion gene or promoter swap). Survival data suggest that patients with AML/MDS and PRDM16 translocations have a poor prognosis despite a simple karyotype and a median age of 65 years. There seems to be an over-representation of late-onset therapy-related myeloid malignancies.
Supporting Information
Fig S1. Translocation of PRDM16 with IKZF1.
Fig S2. Translocation of PRDM16 with WNT3 or NSF.
Fig S3. Translocation of PRDM16 with THADA.
Fig S4. Translocation of PRDM16 with IGL@.
Table SI. Primers used
Table SII. Complete karyotype and FISH data for the 39 patients with translocations involving PRDM16
Table SIII. Gene expression data
Table SIV. Additional gene expression data
| Filename | Description |
|---|---|
| BJH_8918_sm_SupportingInformation.doc11.4 MB | Supporting info item |
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
References
- Aguilo, F., Avagyan, S., Labar, A., Sevilla, A., Lee, D.F., Kumar, P., Lemischka, I.R., Zhou, B.Y. & Snoeck, H.W. (2011) Prdm16 is a physiologic regulator of hematopoietic stem cells. Blood, 117, 5057–5066.
- Barjesteh van Waalwijk van Doorn-Khosrovani, S., Erpelinck, C., Lowenberg, B. & Delwel, R. (2003) Low expression of MDS1-EVI1-like-1 (MEL1) and EVI1-like-1 (EL1) genes in favorable-risk acute myeloid leukemia. Experimental Hematology, 31, 1066–1072.
- Beck, A.H., Lee, C.H., Witten, D.M., Gleason, B.C., Edris, B., Espinosa, I., Zhu, S., Li, R., Montgomery, K.D., Marinelli, R.J., Tibshirani, R., Hastie, T., Jablons, D.M., Rubin, B.P., Fletcher, C.D., West, R.B. & van de Rijn, M. (2010) Discovery of molecular subtypes in leiomyosarcoma through integrative molecular profiling. Oncogene, 29, 845–854.
- Beillard, E., Pallisgaard, N., van der Velden, V.H., Bi, W., Dee, R., van der Schoot, E., Delabesse, E., Macintyre, E., Gottardi, E., Saglio, G., Watzinger, F., Lion, T., van Dongen, J.J., Hokland, P. & Gabert, J. (2003) Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using ‘real-time’ quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) - a Europe against cancer program. Leukemia, 17, 2474–2486.
- Bene, M.C., Castoldi, G., Knapp, W., Ludwig, W.D., Matutes, E., Orfao, A. & van’t Veer, M.B. (1995) Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). Leukemia, 9, 1783–1786.
- Bertrand, P., Bastard, C., Maingonnat, C., Jardin, F., Maisonneuve, C., Courel, M.N., Ruminy, P., Picquenot, J.M. & Tilly, H. (2007) Mapping of MYC breakpoints in 8q24 rearrangements involving non-immunoglobulin partners in B-cell lymphomas. Leukemia, 21, 515–523.
- Bjork, B.C., Turbe-Doan, A., Prysak, M., Herron, B.J. & Beier, D.R. (2010) Prdm16 is required for normal palatogenesis in mice. Human Molecular Genetics, 19, 774–789.
- Bloomfield, C.D., Garson, O.M., Volin, L., Knuutila, S. & de la Chapelle, A. (1985) t(1;3)(p36;q21) in acute nonlymphocytic leukemia: a new cytogenetic-clinicopathologic association. Blood, 66, 1409–1413.
- Bohlander, S.K. (2005) ETV6: a versatile player in leukemogenesis. Seminars in Cancer Biology, 15, 162–174.
- Breems, D.A., Van Putten, W.L., De Greef, G.E., Van Zelderen-Bhola, S.L., Gerssen-Schoorl, K.B., Mellink, C.H., Nieuwint, A., Jotterand, M., Hagemeijer, A., Beverloo, H.B. & Lowenberg, B. (2008) Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype. Journal of Clinical Oncology, 26, 4791–4797.
- Chuikov, S., Levi, B.P., Smith, M.L. & Morrison, S.J. (2010) Prdm16 promotes stem cell maintenance in multiple tissues, partly by regulating oxidative stress. Nature Cell Biology, 12, 999–1006.
- Couture, J.F., Dirk, L.M., Brunzelle, J.S., Houtz, R.L. & Trievel, R.C. (2008) Structural origins for the product specificity of SET domain protein methyltransferases. Proceedings of the National Academy of Sciences of the United States of America, 105, 20659–20664.
- Deluche, L., Joha, S., Corm, S., Daudignon, A., Geffroy, S., Quief, S., Villenet, C., Kerckaert, J.P., Lai, J.L., Preudhomme, C. & Roche-Lestienne, C. (2008) Cryptic and partial deletions of PRDM16 and RUNX1 without t(1;21)(p36;q22) and/or RUNX1-PRDM16 fusion in a case of progressive chronic myeloid leukemia: a complex chromosomal rearrangement of underestimated frequency in disease progression? Genes Chromosomes Cancer, 47, 1110–1117.
- Du, Y., Jenkins, N.A. & Copeland, N.G. (2005) Insertional mutagenesis identifies genes that promote the immortalization of primary bone marrow progenitor cells. Blood, 106, 3932–3939.
- Duhoux, F.P., Ameye, G., Lambot, V., Herens, C., Lambert, F., Raynaud, S., Wlodarska, I., Michaux, L., Roche-Lestienne, C., Labis, E., Taviaux, S., Chapiro, E., Nguyen Khac, F., Struski, S., Dobbelstein, S., Dastugue, N., Lippert, E., Speleman, F., Van Roy, N., De Weer, A., Rack, K., Talmant, P., Richebourg, S., Mugneret, F., Tigaud, I., Mozziconacci, M.J., Laibe, S., Nadal, N., Terré, C., Libouton, J.M., Decottignies, A., Vikkula, M. & Poirel, H.A. (2011) Refinement of 1p36 alterations not involving PRDM16 in myeloid and lymphoid malignancies. PLoS One, doi:10.1371/journal.pone.0026311.
- Hazourli, S., Chagnon, P., Sauvageau, M., Fetni, R., Busque, L. & Hebert, J. (2006) Overexpression of PRDM16 in the presence and absence of the RUNX1/PRDM16 fusion gene in myeloid leukemias. Genes Chromosomes Cancer, 45, 1072–1076.
- Horn, K.H., Warner, D.R., Pisano, M. & Greene, R.M. (2011) PRDM16 expression in the developing mouse embryo. Acta Histochemica, 113, 150–155.
- Hosokawa, Y., Maeda, Y., Ichinohasama, R., Miura, I., Taniwaki, M. & Seto, M. (2000) The Ikaros gene, a central regulator of lymphoid differentiation, fuses to the BCL6 gene as a result of t(3;7)(q27;p12) translocation in a patient with diffuse large B-cell lymphoma. Blood, 95, 2719–2721.
- International Standing Committee on Human Cytogenetic Nomenclature., Shaffer, L.G., Slovak, M.L. & Campbell, L.J. (2009) ISCN 2009: An International System for Human Cytogenetic Nomenclature (2009). Karger, Basel; Unionville, CT.
- Jiang, G.L. & Huang, S. (2000) The yin-yang of PR-domain family genes in tumorigenesis. Histology and Histopathology, 15, 109–117.
- Kajimura, S., Seale, P., Kubota, K., Lunsford, E., Frangioni, J.V., Gygi, S.P. & Spiegelman, B.M. (2009) Initiation of myoblast to brown fat switch by a PRDM16-C/EBP-beta transcriptional complex. Nature, 460, 1154–1158.
- Kim, M., Lee, H.C., Tsedensodnom, O., Hartley, R., Lim, Y.S., Yu, E., Merle, P. & Wands, J.R. (2008) Functional interaction between Wnt3 and Frizzled-7 leads to activation of the Wnt/beta-catenin signaling pathway in hepatocellular carcinoma cells. Journal of Hepatology, 48, 780–791.
- Lacy, P. (2005) The role of Rho GTPases and SNAREs in mediator release from granulocytes. Pharmacology and Therapeutics, 107, 358–376.
- Lahortiga, I., Agirre, X., Belloni, E., Vazquez, I., Larrayoz, M.J., Gasparini, P., Lo Coco, F., Pelicci, P.G., Calasanz, M.J. & Odero, M.D. (2004) Molecular characterization of a t(1;3)(p36;q21) in a patient with MDS. MEL1 is widely expressed in normal tissues, including bone marrow, and it is not overexpressed in the t(1;3) cells. Oncogene, 23, 311–316.
- Livak, K.J. & Schmittgen, T.D. (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2-[Delta][Delta]CT Method. Methods, 25, 402–408.
- Lugthart, S., Groschel, S., Beverloo, H.B., Kayser, S., Valk, P.J., van Zelderen-Bhola, S.L., Jan Ossenkoppele, G., Vellenga, E., van den Berg-de Ruiter, E., Schanz, U., Verhoef, G., Vandenberghe, P., Ferrant, A., Kohne, C.H., Pfreundschuh, M., Horst, H.A., Koller, E., von Lilienfeld-Toal, M., Bentz, M., Ganser, A., Schlegelberger, B., Jotterand, M., Krauter, J., Pabst, T., Theobald, M., Schlenk, R.F., Delwel, R., Dohner, K., Lowenberg, B. & Dohner, H. (2010) Clinical, molecular, and prognostic significance of WHO type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and various other 3q abnormalities in acute myeloid leukemia. Journal of Clinical Oncology, 28, 3890–3898.
- Man, T.K., Lu, X.Y., Jaeweon, K., Perlaky, L., Harris, C.P., Shah, S., Ladanyi, M., Gorlick, R., Lau, C.C. & Rao, P.H. (2004) Genome-wide array comparative genomic hybridization analysis reveals distinct amplifications in osteosarcoma. BMC Cancer, 4, 45.
- Medves, S., Duhoux, F.P., Ferrant, A., Toffalini, F., Ameye, G., Libouton, J.M., Poirel, H.A. & Demoulin, J.B. (2010) KANK1, a candidate tumor suppressor gene, is fused to PDGFRB in an imatinib-responsive myeloid neoplasm with severe thrombocythemia. Leukemia, 24, 1052–1055.
- Mochizuki, N., Shimizu, S., Nagasawa, T., Tanaka, H., Taniwaki, M., Yokota, J. & Morishita, K. (2000) A novel gene, MEL1, mapped to 1p36.3 is highly homologous to the MDS1/EVI1 gene and is transcriptionally activated in t(1;3)(p36;q21)-positive leukemia cells. Blood, 96, 3209–3214.
- Moir, D.J., Jones, P.A., Pearson, J., Duncan, J.R., Cook, P. & Buckle, V.J. (1984) A new translocation, t(1;3) (p36;q21), in myelodysplastic disorders. Blood, 64, 553–555.
- Morishita, K., Parganas, E., William, C.L., Whittaker, M.H., Drabkin, H., Oval, J., Taetle, R., Valentine, M.B. & Ihle, J.N. (1992) Activation of EVI1 gene expression in human acute myelogenous leukemias by translocations spanning 300–400 kilobases on chromosome band 3q26. Proceedings of the National Academy of Sciences of the United States of America, 89, 3937–3941.
- Mullighan, C.G., Goorha, S., Radtke, I., Miller, C.B., Coustan-Smith, E., Dalton, J.D., Girtman, K., Mathew, S., Ma, J., Pounds, S.B., Su, X., Pui, C.H., Relling, M.V., Evans, W.E., Shurtleff, S.A. & Downing, J.R. (2007) Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature, 446, 758–764.
- Mullighan, C.G., Miller, C.B., Radtke, I., Phillips, L.A., Dalton, J., Ma, J., White, D., Hughes, T.P., Le Beau, M.M., Pui, C.H., Relling, M.V., Shurtleff, S.A. & Downing, J.R. (2008) BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature, 453, 110–114.
- Mullighan, C.G., Su, X., Zhang, J., Radtke, I., Phillips, L.A., Miller, C.B., Ma, J., Liu, W., Cheng, C., Schulman, B.A., Harvey, R.C., Chen, I.M., Clifford, R.J., Carroll, W.L., Reaman, G., Bowman, W.P., Devidas, M., Gerhard, D.S., Yang, W., Relling, M.V., Shurtleff, S.A., Campana, D., Borowitz, M.J., Pui, C.H., Smith, M., Hunger, S.P., Willman, C.L. & Downing, J.R. (2009) Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. New England Journal of Medicine, 360, 470–480.
- Nishikata, I., Sasaki, H., Iga, M., Tateno, Y., Imayoshi, S., Asou, N., Nakamura, T. & Morishita, K. (2003) A novel EVI1 gene family, MEL1, lacking a PR domain (MEL1S) is expressed mainly in t(1;3)(p36;q21)-positive AML and blocks G-CSF-induced myeloid differentiation. Blood, 102, 3323–3332.
- Nucifora, G., Begy, C.R., Kobayashi, H., Roulston, D., Claxton, D., Pedersen-Bjergaard, J., Parganas, E., Ihle, J.N. & Rowley, J.D. (1994) Consistent intergenic splicing and production of multiple transcripts between AML1 at 21q22 and unrelated genes at 3q26 in (3;21)(q26;q22) translocations. Proceedings of the National Academy of Sciences of the United States of America, 91, 4004–4008.
- Rippe, V., Drieschner, N., Meiboom, M., Murua Escobar, H., Bonk, U., Belge, G. & Bullerdiek, J. (2003) Identification of a gene rearranged by 2p21 aberrations in thyroid adenomas. Oncogene, 22, 6111–6114.
- Roche-Lestienne, C., Deluche, L., Corm, S., Tigaud, I., Joha, S., Philippe, N., Geffroy, S., Lai, J.L., Nicolini, F.E. & Preudhomme, C. (2008) RUNX1 DNA-binding mutations and RUNX1-PRDM16 cryptic fusions in BCR-ABL+ leukemias are frequently associated with secondary trisomy 21 and may contribute to clonal evolution and imatinib resistance. Blood, 111, 3735–3741.
- Sakai, I., Tamura, T., Narumi, H., Uchida, N., Yakushijin, Y., Hato, T., Fujita, S. & Yasukawa, M. (2005) Novel RUNX1-PRDM16 fusion transcripts in a patient with acute myeloid leukemia showing t(1;21)(p36;q22). Genes Chromosomes Cancer, 44, 265–270.
- Schneider, R., Bannister, A.J. & Kouzarides, T. (2002) Unsafe SETs: histone lysine methyltransferases and cancer. Trends in Biochemical Sciences, 27, 396–402.
- Seale, P., Bjork, B., Yang, W., Kajimura, S., Chin, S., Kuang, S., Scime, A., Devarakonda, S., Conroe, H.M., Erdjument-Bromage, H., Tempst, P., Rudnicki, M.A., Beier, D.R. & Spiegelman, B.M. (2008) PRDM16 controls a brown fat/skeletal muscle switch. Nature, 454, 961–967.
-
Shimizu, S.,
Suzukawa, K.,
Kodera, T.,
Nagasawa, T.,
Abe, T.,
Taniwaki, M.,
Yagasaki, F.,
Tanaka, H.,
Fujisawa, S.,
Johansson, B.,
Ahlgren, T.,
Yokota, J. &
Morishita, K. (2000) Identification of breakpoint cluster regions at 1p36.3 and 3q21 in hematologic malignancies with t(1;3)(p36;q21).
Genes Chromosomes Cancer, 27, 229–238.
10.1002/(SICI)1098-2264(200003)27:3<229::AID-GCC2>3.0.CO;2-0 CAS PubMed Web of Science® Google Scholar
- Shing, D.C., Trubia, M., Marchesi, F., Radaelli, E., Belloni, E., Tapinassi, C., Scanziani, E., Mecucci, C., Crescenzi, B., Lahortiga, I., Odero, M.D., Zardo, G., Gruszka, A., Minucci, S., Di Fiore, P.P. & Pelicci, P.G. (2007) Overexpression of sPRDM16 coupled with loss of p53 induces myeloid leukemias in mice. Journal of Clinical Investigation, 117, 3696–3707.
- Stevens-Kroef, M.J., Schoenmakers, E.F., van Kraaij, M., Huys, E., Vermeulen, S., van der Reijden, B. & van Kessel, A.G. (2006) Identification of truncated RUNX1 and RUNX1-PRDM16 fusion transcripts in a case of t(1;21)(p36;q22)-positive therapy-related AML. Leukemia, 20, 1187–1189.
- Storlazzi, C.T., Albano, F., Guastadisegni, M.C., Impera, L., Muhlematter, D., Meyer-Monard, S., Wuillemin, W., Rocchi, M. & Jotterand, M. (2008) Upregulation of MEL1 and FLJ42875 genes by position effect resulting from a t(1;2)(p36;p21) occurring during evolution of chronic myelomonocytic leukemia. Blood Cells, Molecules, and Diseases, 40, 452–455.
- Swerdlow, S.H. (2008) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. International Agency for Research on Cancer, Lyon, France.
- Takahata, M., Inoue, Y., Tsuda, H., Imoto, I., Koinuma, D., Hayashi, M., Ichikura, T., Yamori, T., Nagasaki, K., Yoshida, M., Matsuoka, M., Morishita, K., Yuki, K., Hanyu, A., Miyazawa, K., Inazawa, J., Miyazono, K. & Imamura, T. (2009) SKI and MEL1 cooperate to inhibit transforming growth factor-beta signal in gastric cancer cells. J Biol Chem, 284, 3334–3344.
- Tefferi, A. (2010) Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia, 24, 1128–1138.
- Warner, D.R., Horn, K.H., Mudd, L., Webb, C.L., Greene, R.M. & Pisano, M.M. (2007) PRDM16/MEL1: a novel Smad binding protein expressed in murine embryonic orofacial tissue. Biochimica et Biophysica Acta, 1773, 814–820.
- Xiao, Z., Zhang, M., Liu, X., Zhang, Y., Yang, L. & Hao, Y. (2006) MEL1S, not MEL1, is overexpressed in myelodysplastic syndromes patients with t(1;3)(p36;q21). Leukemia Research, 30, 332–334.
- Xinh, P.T., Tri, N.K., Nagao, H., Nakazato, H., Taketazu, F., Fujisawa, S., Yagasaki, F., Chen, Y.Z., Hayashi, Y., Toyoda, A., Hattori, M., Sakaki, Y., Tokunaga, K. & Sato, Y. (2003) Breakpoints at 1p36.3 in three MDS/AML(M4) patients with t(1;3)(p36;q21) occur in the first intron and in the 5′ region of MEL1. Genes Chromosomes Cancer, 36, 313–316.
- Yoshida, M., Nosaka, K., Yasunaga, J., Nishikata, I., Morishita, K. & Matsuoka, M. (2004) Aberrant expression of the MEL1S gene identified in association with hypomethylation in adult T-cell leukemia cells. Blood, 103, 2753–2760.
- Zhao, C., Matveeva, E.A., Ren, Q. & Whiteheart, S.W. (2010) Dissecting the N-ethylmaleimide-sensitive factor: required elements of the N and D1 domains. J Biol Chem, 285, 761–772.
Citing Literature
